pH Low Insertion Peptide-exatecan Conjugate CBX-12

DRUG2 trials

Conditions

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Mismatch Repair Proficient Colorectal CarcinomaRefractory Mismatch Repair Proficient Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8

Phase 1

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

RecruitingNCT05691517

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm

Start: 2024-06-12End: 2026-10-15Target: 35Updated: 2026-08-13

Phase 2

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

WithdrawnNCT06730100

National Cancer Institute (NCI)Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8

Start: 2026-02-17End: 2026-12-01Updated: 2025-10-06

Journal of Clinical Oncology2026-01-10

Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-011 citations

pH Low Insertion Peptide-exatecan Conjugate CBX-12

Sponsors

Conditions

Phase 1

Phase 2

Related Papers